The clinical data supporting CT-388 for the indication of obesity in a Phase 2 context can be summarized from the completed parts of a multi-arm, Phase 1/2 clinical trial
They're particularly effective for conditions like rheumatoid arthritis, where they help manage pain, stiffness, and swelling
(2019) suggests that minimizing ultra-processed foods, which are engineered to be hyperpalatable and may dysregulate appetite signaling, can reduce food preoccupation over time and lead to spontaneous reduction in calorie intake
If you are uncomfortable with the current valuations of LLY and NVO (dont be, theyre fine), I would recommend looking into more downstream effects where tailwinds provided by these drugs may not be priced in to expectations by the market and/or consensus estimates yet
Synergy with GLP-1 : When combined, GIP and GLP-1 amplify weight loss, insulin sensitivity, and glucose control better than GLP-1 alone
How do I choose between weight loss drugs and lifestyle changes